Months after $100M series A, Syneron closes $150M round to support peptide platform

Summary: Syneron Bio is on a massive winning streak! After scoring a $3.4 billion deal with AstraZeneca and raising $100 million last year, they just added another $150 million to their bank account. What are they doing with all this cash? They are building a special AI platform to create "macrocyclic peptides." These are known as "Goldilocks" drugs because they are not too big and not too small. They fit perfectly right in the middle, allowing them to fight tough diseases like cancer, metabolic, and autoimmune disorders that other traditional drugs just can't reach. Other big companies like Novartis are also rushing to spend billions on this new type of medicine.

For more details, see rssapp-fiercebiotech-com at fiercebiotech.com/biotech/four-months-after-100m-series-syneron-closes-150m-round-support-peptide-platform (opens in new tab)